All Stories

  1. LC–MS-Based Direct Quantification of MicroRNAs in Rat Blood
  2. Particulate Matter Elevates Ocular Inflammation and Endoplasmic Reticulum Stress in Human Retinal Pigmented Epithelium Cells
  3. Ellagic Acid Prevents Particulate Matter-Induced Pulmonary Inflammation and Hyperactivity in Mice: A Pilot Study
  4. Quantification of venadaparib, a novel PARP inhibitor, in the rat and dog plasma using liquid chromatography/tandem mass spectrometry
  5. Dietary Intervention with Quercetin Attenuates Diesel Exhaust Particle-Instilled Pulmonary Inflammation and Behavioral Abnormalities in Mice
  6. Probiotic, Paraprobiotic, and Hydrolyzed Yeast Mixture Supplementation Has Comparable Effects to Zinc Oxide in Improving Growth Performance and Ameliorating Post-weaning Diarrhea in Weaned Piglets
  7. Application of physiologically‐based pharmacokinetic model approach to predict pharmacokinetics and drug–drug interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine
  8. Formulation Approaches for Improving the Dissolution Behavior and Bioavailability of Tolvaptan Using SMEDDS
  9. The Development and Optimization of Hot-Melt Extruded Amorphous Solid Dispersions Containing Rivaroxaban in Combination with Polymers
  10. Simultaneous Quantification of 3′- and 6′-Sialyllactose in Rat Plasma Using Liquid Chromatography-Tandem Mass Spectrometry and Its Application to a Pharmacokinetic Study
  11. Development and validation of a bioanalytical method of analyzing 3′- and 6′-sialyllactose using liquid chromatography–tandem mass spectrometry in minipig plasma and its application in a pharmacokinetic study
  12. Quantification of triiodothyronine and thyroxine in rat serum using liquid chromatography tandem mass spectrometry
  13. An Exploratory Study of the Relationships Between Diesel Engine Exhaust Particle Inhalation, Pulmonary Inflammation and Anxious Behavior
  14. Gender differences and dose proportionality in the toxicokinetics of udenafil and its active metabolite following oral administration in rodents
  15. Development and Validation of a Bioanalytical Method for 3′- and 6′-Sialyllactose in Minipig Liver and Kidney Using Liquid Chromatography-Tandem Mass Spectrometry and Its Application to Analysis of Tissue Distribution
  16. Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in MET-Addicted Cancer
  17. Determination of motolimod concentration in rat plasma by liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study
  18. Development and Validation of Analytical Method for SH-1242 in the Rat and Mouse Plasma by Liquid Chromatography/Tandem Mass Spectrometry
  19. Development and Evaluation of Raloxifene-Hydrochloride-Loaded Supersaturatable SMEDDS Containing an Acidifier
  20. Identification of metabolites of MDR-1339, an inhibitor of β-amyloid protein aggregation, and kinetic characterization of the major metabolites in rats
  21. Development of a LC–MS/MS method for the determination of CKD-712 in rat plasma: Application to a pharmacokinetic study in rats
  22. Simultaneous quantification of volitinib and gefitinib in rat plasma by HPLC-MS/MS for application to a pharmacokinetic study in rats
  23. Quantification of EC-18, a synthetic monoacetyldiglyceride (1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol), in rat and mouse plasma by liquid-chromatography/tandem mass spectrometry
  24. Development and validation of a liquid chromatography–tandem mass spectrometry method for the assay of tafamidis in rat plasma: Application to a pharmacokinetic study in rats
  25. Specific Inhibition of the Distribution of Lobeglitazone to the Liver by Atorvastatin in Rats: Evidence for a Rat Organic Anion Transporting Polypeptide 1B2–Mediated Interaction in Hepatic Transport
  26. Feasibility of the functional expression of the human organic anion transporting polypeptide 1B1 (OATP1B1) and its genetic variant 521T/C in the mouse liver
  27. Subacute toxicity evaluation of KR-33493, FAF1 inhibitor for a new anti-parkinson's disease agent, after oral administration in rats and dogs
  28. The identification of lobeglitazone metabolites in rat liver microsomes and the kinetics of the in vivo formation of the major metabolite M1 in rats
  29. A novel HPLC–MS/MS method for the simultaneous determination of astemizole and its major metabolite in dog or monkey plasma and application to pharmacokinetics
  30. Kinetics of the Absorption, Distribution, Metabolism, and Excretion of Lobeglitazone, a Novel Activator of Peroxisome Proliferator-Activated Receptor Gamma in Rats
  31. Gender differences in the hepatic elimination and pharmacokinetics of lobeglitazone in rats
  32. Development of QTc prolongation model incorporating circadian rhythm using harmonic model
  33. QUANTIFICATION OF ZABOFLOXACIN IN RAT PLASMA USING HPLC-UV DETECTOR AND ITS APPLICATION TO A PHARMACOKINETIC STUDY
  34. Embryotoxicity and Toxicokinetics of the Antimalarial Artesunate in Rats
  35. Milk Transfer and Toxicokinetics of Valproic Acid in Lactating Cynomolgus Monkeys
  36. 1′-Acetoxychavicol Acetate Isolated from Alpinia galanga Ameliorates Ovalbumin-Induced Asthma in Mice
  37. Self-microemulsifying drug-delivery system for improved oral bioavailability of pranlukast hemihydrate: preparation and evaluation
  38. Development of a LC–MS method for quantification of FK-3000 and its application to in vivo pharmacokinetic study in drug development
  39. The Zanthoxylum schinifolium seed oil modulates immune function under the biological safety level
  40. QUANTIFICATION OF CILNIDIPINE IN HUMAN PLASMA BY LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY
  41. Quantification of oltipraz using liquid chromatography–tandem mass spectrometry and its application to a pharmacokinetic study in rat plasma
  42. Stephania delavayi Diels. inhibits breast carcinoma proliferation through the p38 MAPK/NF-κB/COX-2 pathway
  43. Biological safety and B cells activation effects of Zanthoxylum schinifolium
  44. Quantitative determination of sirolimus in dog blood using liquid chromatography–tandem mass spectrometry, and its applications to pharmacokinetic studies
  45. The stoichiometric relationship between KCNH-2 and KCNE-2 in IKr channel formation
  46. Simultaneous gene expression signature of heart and peripheral blood mononuclear cells in astemizole-treated rats
  47. Quantification of CKD-501, lobeglitazone, in rat plasma using a liquid-chromatography/tandem mass spectrometry method and its applications to pharmacokinetic studies
  48. Determination of Belotecan in the Plasma, Bile, and Urine of Rats by High-Performance Liquid Chromatography with Fluorescence Detection and Its Application to a Pharmacokinetic Study
  49. Assessment of General and Cardiac Toxicities of Astemizole in Male Cynomolgus Monkeys: Serum Biochemistry and Action Potential Duration
  50. Reliable and fast quantitative analysis of active ingredient in pharmaceutical suspension using Raman spectroscopy